GLP-1 Weight-Loss Pills Could Transform Treatment
A new era of weight-loss treatment could soon trade needles for pills. Drugmakers behind GLP-1 injections like Wegovy…
How the ‘Ozempic effect’ is reshaping the global economy
Michael Siluk/Alamy The new wave of weight-loss drugs has taken the world by storm. From Novo Nordisk’s Ozempic…
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
The overall stock market keeps reaching new heights, but some of its components are having a lousy year.…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…
Weight-loss drugs becoming better value for money, says watchdog
Popular GLP-1 weight-loss injections are now delivering greater value, according to a new report by a leading pharmaceutical…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Drugmaker halves price of Ozempic for Americans amid Trump crackdown
The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made…
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made…
Novo Nordisk’s diabetes and weight loss drug sales growth decelerates
Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of…